Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Picankibart in Moderate-to-Severe Palmoplantar Pustulosis
NCT07552454Recruiting
- Sponsor
- Xijing Hospital
- Start
- Apr 2026
- Primary completion
- Oct 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Open-label, single-arm trial of picankibart in palmoplantar pustulosis (PPP), sponsored by Xijing Hospital. Primary endpoint: Palmoplantar Pustular Psoriasis Area and Severity Index at 16 weeks. Started Apr 2026; status: recruiting.
02
Drugs
picankibart
03
Conditions
palmoplantar pustulosis (PPP)
Beyond the preview
Go deeper on NCT07552454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07552454.